The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies

Blood

Volumn 96, Issue 3, 2000, Pages 808-822

  Willis, T G ^a   Dyer, M J S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 6;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; BURKITT LYMPHOMA; CELL CYCLE; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MYELOMA; PRIORITY JOURNAL; REVIEW;

EID: 0034254687     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.3.808     Document Type: Review

References (214)

1. Translocations, cancer and the puzzle of specificity
2. The critical role of chromosome translocations in human leukemias
3. 14q+ Marker-positive lymphoid cancer and its sub-classes
4. Cytogenetic analysis of 363 consecutively ascertained diffuse large B- cell lymphomas
5. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type
6. The pathogenesis of Burkitt's lymphoma
7. Visualization of mono-allelic chromosomal aberrations 3' and 5' of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization
8. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
9. Different regions of the immunoglobulin heavy chain locus are involved in chromosomal translocations in different pathogenic forms of Burkitt lymphoma
10. BCL2 translocations in leukemias of mature B cells
11. Interphase and metaphase detection of the breakpoint of 14q32 translocations in B-cell malignancies by double-color fluorescence in situ hybridization
12. DNA fiber-FISH analysis of immunoglobulin class switching in B cell neoplasia: Aberrant C(H) gene rearrangements in follicle center cell lymphoma
13. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization
14. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization
15. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping
16. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma
17. Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma
18. Concurrent activation of Myc and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus
19. Molecular cloning of complex chromosomal translocation t(8;14;12)(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon
20. Deregulation of BCL6 in non-Hodgkin lymphoma by insertion of IGH sequences in complex translocations involving band 3q27
21. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization
22. Insertion of excised lgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell
23. BCL2 insertion into the IGH locus in follicular lymphoma
24. Regulated genomic instability and neoplasia in the lymphoid lineage
25. Preferential clustering of chromosomal breakpoints in Burkitt's lymphomas and L3 type acute lymphoblastic leukemias with a t(8;14) translocation
26. Chromosomal translocations in lymphoid neoplasia: A reappraisal of the recombinase model
27. Somatic hypermutation in normal and transformed human B cells
28. V(D)J recombinase activity in a subset of germinal center B lymphocytes
29. Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines
30. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene
31. BCL2 complex rearrangement in follicular lymphoma: Translocation mbr/JH and deletion in the vcr region of the same BCL2 allele
32. Jumping translocation breakpoint regions lead to amplification of rearranged Myc
33. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts
34. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf- Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma
35. Unusual deletions within the immunoglobulin heavy-chain locus in acute leukemias
36. Activation of the interleukin-3 gene by chromosomal translocation in acute lymphocytic leukemia with eosinophilia
37. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: Clinical correlations
38. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21
39. Inactivation of the P16INK4/MTS1 gene by a chromosome translocation t(9;14)(p21-22;q11) in an acute lymphoblastic leukemia of B-cell type
40. A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16(INK4A)/p15(INK4B) tumor suppressor and immunoglobulin heavy chain genes: TGFβ/IL-7 inhibitory signaling mechanism
41. MYC rearrangements in histologically progressed follicular lymphomas
42. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas
43. Myc and Myb
44. Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies
45. Overexpression of PRAD1 in a mantle zone lymphoma patient with a t(11;22)(q13;q11) translocation
46. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines
47. Rapid amplification of rearrangements of the IGHJ locus by long- distance inverse PCR
48. Refinement of the BCL2/immunoglobulin heavy chain fusion gene in t(14;18)(q32;q21) by polymerase chain reaction amplification for long targets
49. Rearrangement of the 5' cluster region of the BCL2 gene in lymphoid neoplasm: A summary of nine cases
50. The IgG Fc receptor, FcRIIB is a target for deregulation by chromosomal translocation in malignant lymphoma
51. Prognostic significance of BCL2 protein expression and BCL2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
52. Prognostic significance of BCL2 expression and BCL2 major breakpoint region rearrangement in diffuse largo cell non-Hodgkin's lymphoma: A British National Lymphoma investigation study
53. Translocations involving band 3q27 and Ig gene regions in non- Hodgkin's lymphoma
54. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas
55. Alterations of a zinc-finger encoding gene, BCL6, in diffuse large- cell lymphoma
56. Gene involved in the 3q27 translocation associated with B-cell lymphoma, BCL5, encodes a Kruppel-like zinc-finger protein
57. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma
58. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma
59. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes
60. Nonimmunoglobulin gene hypermutation in germinal center B cells
61. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma
62. LAZ3 rearrangements in non-Hodgkin's lymphoma: Correlation with histology, immunophenotype, karyotype, and clinical outcome
63. Clinical relevance of BCL2, BCL6, and Myc rearrangements in diffuse large B-cell lymphoma
64. BCL-6 protein is expressed in germinal-center B cells
65. BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts
66. The POZ domain: A conserved protein-protein interaction motif
67. The BTB domain, found primarily in zinc finger proteins, defines an evolutionary conserved family that includes several developmentally regulated genes in Drosophila
68. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: A novel function for the BTB/POZ domain as an autonomous repressing domain
69. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor
70. BCL-6 is phosphorylated at multiple sites in its serine- and proline- clustered region by mitogen-activated protein kinase (MAPK) in vivo
71. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor
72. The BCL-6 proto-oncogene controls germinal-centre formation and Th2- type inflammation
73. Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication loci
74. BCL8, a novel gene involved in translocations affecting band 15q11-13 in diffuse large-cell lymphoma
75. Chromosomal aberrations in non-Hodgkin's lymphoma: Biological and clinical correlations
76. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50
77. t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation
78. Clusters of chromosome 9 aberrations are associated with clinico- pathological subsets of non-Hodgkin's lymphoma
79. Deregulation of PAX-5 by translocation of the Eμ enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma
80. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene
81. Regression of primary low-grade B-cell gastric lymphoma of mucosa- associated lymphoid tissue type after eradication of Helicobacter pylori
82. BCL 10 is involved in chromosomal translocation t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types
83. Inactivating mutations and overexpression of BCL 10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32)
84. CIPER, a novel NF-KB-activating protein containing a caspase recruitment domain with homology to herpesvirus-2 protein E10
85. Involvement of a human endogenous retroviral sequence (THE-7) in a t(7;14)(q21;q32) chromosomal translocation associated with a B-cell chronic lymphocytic leukemia
86. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations
87. Mammalian G cyclins
88. BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: A molecular and cytogenetic study
89. Molecular cloning and characterization of the t(2;14) translocation associated with childhood chronic lymphocytic leukemia
90. Cyclin D2 promoter disrupted by t(12;22)(p13; q11.2) during transformation of chronic lymphocytic leukaemia to non-Hodgkin's lymphoma
91. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
92. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene
93. The FGF family of growth factors and oncogenes
94. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism
95. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3
96. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia
97. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis
98. Prevention of myeloma cell apoptosis by ectopic BCL2 expression or interieukin 6-mediated up-regulation of bcl-xL
99. Detection of MUM1/IRF4-IgH fusion in multiple myeloma
100. Deregulation of MUM/IRF4 by chromosomal translocation in multiple myeloma
101. Structurally similar but functionally distinct factors, IRF-1 and IRF- 2, bind to the same regulatory elements of IFN and IFN-inducible genes
102. Requirement for the transcription factor LSlRF/IRF4 for mature B and T lymphocyte function
103. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma
104. Structure-function analysis of the maf oncogene product, a member of the b-Zip protein family
105. Two novel genes related to the Fc receptor family involved in the t(1;14)(q21;q32) chromosomal translocation in multiple myeloma
106. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
107. p53 Is frequently mutated in Burkitt's lymphoma cell lines
108. p53 In hematologic malignancies
109. The BCL2 protein family: Arbiters of cell survival
110. BCL2 family: Regulators of cell death
111. BCL2 is an inner mitochondrial membrane protein that blocks programmed cell death
112. X-ray and NMR structure of human Bcl-(XL), an inhibitor of programmed cell death
113. Inhibition of Bax channel-forming activity by BCL2
114. Bcl-(XL) forms an ion channel in synthetic lipid membranes
115. Channel formation by anti-apoptotic protein BCL2
116. BCL2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation
117. Dereguluted BCL2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B cell population
118. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)
119. Novel primitive lymphoid turnouts induced in transgenic mice by cooperation between myc and BCL2
120. BCL2 has a cell cycle inhibitory function separable from its enhancement of cell survival
121. The anti-apoptosis function of BCL2 can be genetically separated from its inhibitory effect on cell cycle entry
122. A link between cell cycle and cell death: Bax and BCL2 modulate Cdk2 activation during thymocyte apoptosis
123. Somatic point mutations in the translocated BCL2 genes of non- Hodgkin's lymphomas and lymphocytic leukemias: Implications for mechanisms of tumor progression
124. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11)
125. Induction of apoptosis in fibroblasts by c-myc protein
126. Tumor surveillance via the ARF-p53 pathway
127. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
128. The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice
129. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
130. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
131. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins
132. 1-phase progression
133. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points
134. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27
135. 1
136. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression
137. 1 phase control in B-cell neoplasms carrying the t(11;14) translocation
138. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene
139. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice
140. Constitutive nuclear translocation of NF-KB in B cells in the absence of IκB degradation
141. Mutations in the IκBα gene in Hodgkin's disease suggest a tumor suppressor role for IκBα
142. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses
143. NF-κB and Rel proteins in innate immunity
144. Control of apoptosis by Rel/NF-κB transcription factors
145. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40
146. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1
147. Site-specific phosphorylation of IκBα by a novel ubiquitination- dependent protein kinase activity
148. Activation of phosphatidylinositol 3-kinase in reponse to interleukin- 1 leads to phosphorylation and activation of the NF-κB p65/RelA subunit
149. Structural alterations of the NF-κB transcription factor lyt-10 in lymphoid malignancies
150. Hererogeneous chromosomal alterations generate 3' truncations of the NF-κB2/lyt-10 gene in lymphoid malignancies
151. Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators
152. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2
153. Nuclear factor (NF)-κB2/p52 is required for normal splenic microarchitecture and B cell-mediated immune responses
154. Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture
155. The CARD domain: A new apoptotic signaling motif
156. Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment
157. Solution structure of Apaf-1 CARD and its interaction with caspase-9 CARD: A structural basis for specific adaptor/caspase interaction
158. Crystal structure of Apaf-1 caspase recruitment domain: An alpha- helical Greek key fold for apoptotic signaling
159. RAIDD is a new 'death' adaptor molecule
160. CRADD, a novel human apoptotic adaptor molecule for caspase-2,and FasL/tumor necrosis factor receptor-interacting protein RIP
161. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex intitiates an apoptotic cascade
162. CLAP, a novel caspase recruitment domain-containing protein in the tumour necrosis factor receptor pathway, regulates NF-(K)B activation and apoptosis
163. c-E10 is a caspase-recruitment domain-containing protein that interacts with components of death receptors signaling pathway and activates nuclear factor-(K)B
164. mE10, a novel caspase recruitment domain-containing proapoptotic molecule
165. BCL10 gene mutation in lymphoma
166. BCL10 expression in normal and neoplastic lymphoid tissue [abstract]
167. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases
168. Alternative splicing determines the intracellular localization of the novel nuclear protein Nop30 and its interaction with the splicing factor SRp30c
169. Characterization of an immediate early gene induced in adherent monocytes that encodes an IκB-like activity
170. Candidate proto-oncogena bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-κB
171. IκBβ regulates the persistent response in a biphasic activation of NF-κB
172. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-κB proteins
173. The oncoprotein BCL3 directly transactivates through (K)B motifs via association with DNA-binding pSB homodimers
174. BCL3, a member of IκB proteins, has distinct specificity towards the Rel family of proteins
175. The bcl-3 proto-oncogene encodes a nuclear IκB-like molecule that preferentially interacts with NF-κB p50 and p52 in a phosphorylation- dependent manner
176. The oncoprotein Bcl-3 can facilitate NF-κB-mediated transactivation by removing inhibiting p50 homodimers from select κB sites
177. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers
178. Constitutive expression of Bcl-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo
179. Diverse effects of BCL3 phosphorylation on its modulation of NF-κB p52 homodimer binding to DNA
180. The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear coregulators
181. Critical roles for the Bcl-3 oncoprotein in T-cell-mediated immunity, splenic microarchitecture, and germinal center reactions
182. Immunological defects in mice with a targeted disruption in Bcl-3
183. Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice
184. An essential role for NF-κB in preventing TNF-α-induced cell death
185. TNF-and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
186. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras
187. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes
188. 1 transition in mouse fibroblasts
189. Repression of NF-κB impairs HeLa cell proliferation by functional interference with cell cycle regulators
190. 1-to-S phase transition
191. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1
192. Inhibitory pathways triggered by ITIM-containing receptors
193. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RllB modulates B-cell receptor signaling
194. Structure and expression of human IgG FcRII (CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes
195. Cross-linking of B lymphocyte Fc gamma receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis
196. Negative signaling in B lymphocytes induces tyrosine phosphorylation of the 145-kDa inositol polyphosphate 5-phosphatase, SHIP
197. Role of the isositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc-gamma-RIIB
198. Phosphatidylinositol-3,4,5-triphosphate (Ptdins-3,4,5-P3)/Tec kinase- dependent calcium signaling pathway A target for SHIP-mediated inhibitory signals
199. SHIP modulates immune receptor responses by regulating membrane association of Btk
200. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells
201. FcgammaRIIb modulation of surface immunoglobulin-induced Akt activation in murine B cells
202. 2+ following B-cell receptor activation
203. SHIP recruitment attenuates FcγRIIB-induced B cell apoptosis
204. Fc receptor off-signal in the B cell involves apoptosis
205. Role of the transcription factor BSAP (Pax-5) in B-cell development
206. The B cell-specific transcription factor BSAP regulates B cell proliferation
207. CD19 regulates B lymphocyte responses to transmembrane signals
208. Genetic pathways to recurrent chromosomal translocations in murine lymphoma invokes V(D)J recombination
209. Dynamic repositioning of genes in the nucleus of lymphocytes preparing for cell division
210. Distribution of ABL and BCR genes in cell nuclei of normal and irradiated lymphocytes
211. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals
212. Immunoglobulin/myc recombinations in murine Peyer's patch follicles
213. MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets
214. MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma